In this study, we have investigated potential synergy between Zeb1 and Zeb2 deletion in modulating AML survival but could not obtain any evidence that the loss of Zeb1/2 was more significant than Zeb2 deletion alone in extending survival in MLL-AF9 settings. The gene discussed is MLLT3; the disease is acute myeloid leukemia.